1447 related articles for article (PubMed ID: 16796401)
1. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
[TBL] [Abstract][Full Text] [Related]
2. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
[TBL] [Abstract][Full Text] [Related]
4. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
[TBL] [Abstract][Full Text] [Related]
5. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
[TBL] [Abstract][Full Text] [Related]
6. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus.
Rockx B; Donaldson E; Frieman M; Sheahan T; Corti D; Lanzavecchia A; Baric RS
J Infect Dis; 2010 Mar; 201(6):946-55. PubMed ID: 20144042
[TBL] [Abstract][Full Text] [Related]
7. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
[TBL] [Abstract][Full Text] [Related]
8. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM
J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212
[TBL] [Abstract][Full Text] [Related]
9. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
[TBL] [Abstract][Full Text] [Related]
10. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
He Y; Li J; Heck S; Lustigman S; Jiang S
J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid substitution in the S1 and S2 Spike protein domains determines the neutralization escape phenotype of SARS-CoV.
Mitsuki YY; Ohnishi K; Takagi H; Oshima M; Yamamoto T; Mizukoshi F; Terahara K; Kobayashi K; Yamamoto N; Yamaoka S; Tsunetsugu-Yokota Y
Microbes Infect; 2008 Jul; 10(8):908-15. PubMed ID: 18606245
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
Sui J; Li W; Roberts A; Matthews LJ; Murakami A; Vogel L; Wong SK; Subbarao K; Farzan M; Marasco WA
J Virol; 2005 May; 79(10):5900-6. PubMed ID: 15857975
[TBL] [Abstract][Full Text] [Related]
13. SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity.
Liang MF; Du RL; Liu JZ; Li C; Zhang QF; Han LL; Yu JS; Duan SM; Wang XF; Wu KX; Xiong ZH; Jin Q; Li DX
Biomed Environ Sci; 2005 Dec; 18(6):363-74. PubMed ID: 16544518
[TBL] [Abstract][Full Text] [Related]
14. Chicken single-chain variable fragments against the SARS-CoV spike protein.
Lee YC; Leu SJ; Hu CJ; Shih NY; Huang IJ; Wu HH; Hsieh WS; Chiang BL; Chiu WT; Yang YY
J Virol Methods; 2007 Dec; 146(1-2):104-11. PubMed ID: 17643500
[TBL] [Abstract][Full Text] [Related]
15. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity.
Buchholz UJ; Bukreyev A; Yang L; Lamirande EW; Murphy BR; Subbarao K; Collins PL
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9804-9. PubMed ID: 15210961
[TBL] [Abstract][Full Text] [Related]
16. Epitope mapping and biological function analysis of antibodies produced by immunization of mice with an inactivated Chinese isolate of severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Chou TH; Wang S; Sakhatskyy PV; Mboudjeka I; Lawrence JM; Huang S; Coley S; Yang B; Li J; Zhu Q; Lu S
Virology; 2005 Mar; 334(1):134-43. PubMed ID: 15749129
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
[TBL] [Abstract][Full Text] [Related]
18. Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing.
Elshabrawy HA; Coughlin MM; Baker SC; Prabhakar BS
PLoS One; 2012; 7(11):e50366. PubMed ID: 23185609
[TBL] [Abstract][Full Text] [Related]
19. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
[TBL] [Abstract][Full Text] [Related]
20. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
Coughlin M; Lou G; Martinez O; Masterman SK; Olsen OA; Moksa AA; Farzan M; Babcook JS; Prabhakar BS
Virology; 2007 Apr; 361(1):93-102. PubMed ID: 17161858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
